Hyloris PharmaceuticalsLTS:0AB6 -0.66%21 PS Ratio is 17.58 as of Jul. 13, 2026, which is 89% below its 10-year median of 156.00. GuruFocus rates LTS:0AB6 with a GF Score™ of 21/100 and a GF Value™ of €9.57 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 930 Biotechnology companies, Hyloris Pharmaceuticals ranks worse than 63.23% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Hyloris Pharmaceuticals's share price is €4.50.
Hyloris Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.26. Hence, Hyloris Pharmaceuticals's PS Ratio for today is 17.58.
Good Sign:
Hyloris Pharmaceuticals SA stock PS Ratio (=18.09) is close to 10-year low of 17.22.
The historical rank and industry rank for Hyloris Pharmaceuticals's PS Ratio or its related term are showing as below:
LTS:0AB6'
s PS Ratio Range Over the Past 10 Years
Min: 17.22 Med: 156 Max: 2695
Current: 18.16
During the past 10 years, Hyloris Pharmaceuticals's highest PS Ratio was 2695.00. The lowest was 17.22. And the median was 156.00.
LTS:0AB6's PS Ratio is ranked worse than 63.23% of 930
companies
in the Biotechnology industry
Industry Median: 9.49
vs LTS:0AB6: 18.16
During the past 10 years, Hyloris Pharmaceuticals's highest 3-Year average Revenue per Share Growth Rate was 210.70% per year. The lowest was -3.90% per year. And the median was 100.15% per year.
Back to Basics: PS Ratio
Hyloris Pharmaceuticals (LTS:0AB6) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Hyloris Pharmaceuticals's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hyloris Pharmaceuticals PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Hyloris Pharmaceuticals's PS Ratio distribution charts can be found below:
* The bar in red indicates where Hyloris Pharmaceuticals's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Hyloris Pharmaceuticals's Share Price of today is €4.50.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Hyloris Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was €0.26.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Hyloris Pharmaceuticals (LTS:0AB6) has a PS Ratio of 17.58 as of Jul. 13, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Hyloris Pharmaceuticals and its competitors. This is 89% below median its historical median of 156.00. Over the past decade, Hyloris Pharmaceuticals' PS Ratio has ranged from 17.22 to 2,695.00. According to the industry distribution chart, Hyloris Pharmaceuticals ranks #588 out of 930 companies in the Biotechnology industry, placing it in the top 63.2%.
Is Hyloris Pharmaceuticals' PS Ratio too high?
Hyloris Pharmaceuticals' current PS Ratio of 17.58 is 89% below median its 10-year median of 156.00. Over the past 10 years, this metric has ranged from a low of 17.22 to a high of 2,695.00. The Biotechnology industry median PS Ratio is 9.49. Hyloris Pharmaceuticals' value of 17.58 is 85.2% above this industry median. Based on the distribution chart, Hyloris Pharmaceuticals ranks #588 out of 930 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Hyloris Pharmaceuticals has a GF Score™ of 21/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Hyloris Pharmaceuticals' PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Hyloris Pharmaceuticals ranks #588 out of 930 companies for PS Ratio. This places Hyloris Pharmaceuticals in the lower half of its industry. The industry median PS Ratio is 9.49. Hyloris Pharmaceuticals' value of 17.58 is 85.2% above this benchmark. Historically, Hyloris Pharmaceuticals' own PS Ratio has ranged from 17.22 to 2,695.00 over the past decade. While the company's 10-year median is 156.00 vs. the industry median of 9.49, Hyloris Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.49, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hyloris Pharmaceuticals's current PS Ratio of 17.58 is 85.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Hyloris Pharmaceuticals and its competitors. For the Biotechnology industry, the median PS Ratio is 9.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hyloris Pharmaceuticals's current PS Ratio is 17.58, which is 89% below median its own 10-year median of 156.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hyloris Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Hyloris Pharmaceuticals (LTS:0AB6) is currently considered Possible Value Trap. The stock's GF Value™ is €9.57, compared to a current price of €4.50 — trading 53% below its estimated fair value. The current PS Ratio is 17.58, which is 89% below median its 10-year median of 156.00 and 85.2% above the Biotechnology industry median of 9.49. Hyloris Pharmaceuticals' overall GF Score™ is 21/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Hyloris Pharmaceuticals (LTS:0AB6), the current PS Ratio is 17.58 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hyloris Pharmaceuticals (LTS:0AB6) Overvalued in 2026?
Based on GuruFocus' analysis, Hyloris Pharmaceuticals stock appears to be undervalued.
The current stock price of €4.50 is trading 53% below its estimated GF Value™ of €9.57.
GuruFocus considers Hyloris Pharmaceuticals to be Possible Value Trap.
Key valuation signals for LTS:0AB6:
PS Ratio: 17.58 (89% below median its 10-year median of 156.00)
GF Value™: €9.57 vs. price of €4.50 (53% below fair value)
Industry Position: 85.2% above the Biotechnology median (#588 of 930)
No single metric tells the full story. See the LTS:0AB6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hyloris Pharmaceuticals SA is an early-stage specialty pharmaceutical company focused on adding value to the healthcare system by reformulating pharmaceuticals. The company develops proprietary products it believes offer advantages compared to available alternatives, to address the underserved medical needs of patients, hospitals, physicians, payors, and other stakeholders in the healthcare system. Its portfolio spans areas such as cardiovascular, other reformulations, and established markets (high-barrier generics). It has three early commercial-stage products, Sotalol IV for the treatment of atrial fibrillation, Podofilox Ge, and Maxigesic IV. Its revenue is mainly generated in the United States.
21GF Score
Get the complete analysis for LTS:0AB6
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0AB6 has been successfully added to your 
